Transitional ePRO Diary Liver (Transitional-ePRO)

Integrated System for Patients Who Belong the Transition to Adult Services and Are Undergoing a Liver Transplant

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06342557

Acronym

MACROLIVER

Enrollment

250

Registered

2024-04-02

Start date

2024-03-28

Completion date

2034-02-21

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplant

Brief summary

The study is part of the MACROLIVER Project, whose main objective is to create a digital tool for patients and caregivers for the management of liver disease that allows the optimization of therapy and/or the treatment process, even remotely. Such a tool not only reduces the movement of patients who are by definition fragile, but also enables the optimization of access and care by a multidisciplinary team. This tool is intended to support doctors and patients, but in no way replaces normal clinical practice. This study aims to explore the specificities of patients experiencing the transition from the pediatric ward to the adult ward in order to identify risk and protective factors that influence psychological well-being at both an individual and relational level. In order to gather all the information about the patients attending the transitional clinic and to obtain a more complete and truthful clinical-psychological picture, the study also includes the collection of retrospective data of the transplanted patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

14 Years to 20 Years

Healthy volunteers

Inclusion criteria

* patients between the ages of 14 and 20 who have been transplanted at the ASST-PG23 transplant center or are awaiting a liver transplant and belong to the transition to adult services * signed informed consent * proven use of the APPs (to be assessed based on the last 2 weeks)

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
four-item Morisky Medication Adherence Scale (MGLS)	3 months	MGLS is used to assess non-adherence to therapy. The MGLS includes four questions with yes/no response options, resulting in a score from 0 to 4. Based on this score, there are 3 levels of adherence: high, medium and low adherence with 0, 1-2 and 3-4 points respectively. Scores below 2 indicate a lack of adherence to therapy, while scores greater than or equal to 3 indicate adherence to therapy.

Countries

Italy

Contacts

CONTACTPietro Giani, BS

gastroenterologia.liver@asstpg23.it035.2675134

PRINCIPAL_INVESTIGATORStefano Fagiuoli, MD

ASST-PG23

Outcome results